Furthermore, existing literature comparing IHC and NGS for HER-2 detection in gastric cancer have shown that 16.5% of patients were HER-2 3+ by IHC, while NGS identified HER-2 mutations in 4.1% and copy number increases in 14.9% of patients. This evidence concerns the gene ERBB2 and gastric cancer.